Ascenta Capital Partners

Ascenta Capital is a New York-based venture capital firm exclusively focused on the life sciences and biotechnology sectors. Established in 2023 by Evan Rachlin and Bobby Thomas, both former partners at Bain Capital Life Sciences, the firm manages a significant inaugural fund dedicated to transformative medical innovation. Ascenta invests across the company lifecycle, participating in both private venture financings and public market opportunities. The firm's investment strategy is rooted in deep scientific and clinical due diligence, targeting therapies with the potential to redefine standards of care in oncology, neurology, and immunology. By leveraging the founders' extensive experience in company building and capital markets, Ascenta Capital partners with management teams to accelerate the development of next-generation medicines.